The efficiency and safety analysis of ibandronate at the initial loading dose for metastatic bone pain induced by non-small cell lung cancer / 肿瘤

ABSTRACT

Objective: To evaluate the efficiency and safety of ibandronate at the initial loading dose in the treatment of metastatic bone pain (MBP) induced by non-small cell lung cancer (NSCLC). Methods: Thirty cases of NSCLC patients who were admitted to our hospital from May 2006 to July 2007 were retrospectively analyzed. They received loading dose of ibandronate for MBP treatment. Ibandronate was given to the patients intravenously at initial loading dose of 6 mg for more than 15 min on 3 consecutive days. Then ibandronate was administered repeatedly at 6 mg every 3 to 4 months. The response time, pain score, QOL score, daily morphine consumption dose were recorded. The serum markers such as calcium, creatinine, alkaline phosphatase (AKP) were monitored. Results: Twenty nine cases were eligible to evaluate the efficiency and safety. Among them, the MBP of 25 cases (86.2%) were relieved. Their average response time was 2.9 ± 0.8 days. The pain score was significantly decreased after treatment and the life qualities of patients were markedly improved (P <0.001). The morphine consumption dose was reduced by about 20 to 40 mg in 4 cases after treatment. The serum calcium level increased in 7 patients before treatment and declined to the normal level after treatment. The adverse reaction was relieved after treatment and no renal toxicity was observed. Conclusion: Administration of ibandronate at initial loading dose had quick on-set and mild side effects. It could significantly relieve metastasis bone pain and improve QOL, reduce the morphine consumption dose and avoid morphine-induced adverse reaction, and effectively decrease serum calcium level. Administration of ibandronate at initial loading dose is a new promising option for treatment of the MBP in NSCLC.